Source: Marketing Authorisation Holder Revision Year: 2018 Publisher: Pfizer Laboratories (Pty) Ltd, 85 Bute Lane, Sandton, 2196, South Africa
PRANDIN E2 1mg (Vaginal Gel).
PRANDIN E2 2Mg (Vaginal Gel).
| Pharmaceutical Form |
|---|
|
Vaginal Gel. |
Each unit dose of 3,0 grams (2,5 ml) contains 1,0 mg or 2,0 mg dinoprostone.
| Active Ingredient | Description | |
|---|---|---|
| Dinoprostone |
|
| List of Excipients |
|---|
|
|
A colourless, semi-translucent, viscous gel.
PRANDIN E2 1 mg or 2 mg Vaginal Gel is supplied as a semi-translucent, thixotropic sterile gel as follows: 1 mg or 2 mg PGE2 per 3 g in syringes for intravaginal application.
Pfizer Laboratories (Pty) Ltd, 85 Bute Lane, Sandton, 2196, South Africa
PRANDIN E2 1 mg Vaginal Gel: W/19/455
PRANDIN E2 2 mg Vaginal Gel: W/19/456
Date of registration: 12 September 1990
Date of last SAHPRA approval: 11 August 2006
| Drug | Countries | |
|---|---|---|
| PRANDIN E2 | United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
